US Broker Ratings

Bicycle Therapeutics (BCYC) Investor Outlook: Uncovering a 176% Potential Upside in Biotech Innovation

Bicycle Therapeutics plc (NASDAQ: BCYC), a clinical-stage pharmaceutical company, stands at the forefront of pioneering new classes of medicines for diseases underserved by existing therapies. With a market capitalization of..

Prothena Corporation plc (PRTA) Stock Analysis: Potential 28.84% Upside Amidst Promising Clinical Pipeline

Prothena Corporation plc (NASDAQ: PRTA), a Dublin-based biotechnology company, is capturing investor attention with its innovative approach to tackling diseases caused by protein dysregulation. Despite recent volatility in its stock..

Day One Biopharmaceuticals, Inc (DAWN) Stock Analysis: A 215% Potential Upside Awaits Patient Investors

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN), a burgeoning player in the healthcare sector, is making significant strides in the biotechnology industry. With a market capitalization of $765.17 million, this U.S.-based..

LifeMD, Inc. (LFMD) Stock Analysis: Exploring a Potential 100% Upside as Telehealth Expands

LifeMD, Inc. (LFMD) is a burgeoning player in the healthcare sector, specifically within the health information services industry. With a market cap of $304.89 million, LifeMD operates as a direct-to-patient..

Spyre Therapeutics, Inc. (SYRE) Stock Analysis: A Biotech Innovator with 137.90% Potential Upside

Spyre Therapeutics, Inc. (NASDAQ: SYRE), a promising player in the biotechnology sector, is grabbing attention with its cutting-edge research in inflammatory bowel disease (IBD) and a remarkable 137.90% potential upside..

Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Exploring a 198% Upside Potential in Biotechnology

Nurix Therapeutics, Inc. (NASDAQ: NRIX), a San Francisco-based biotechnology company, is capturing investor attention with its innovative approach to drug discovery and development. As a clinical-stage biopharmaceutical company, Nurix focuses..

Sonida Senior Living, Inc. (SNDA) Stock Analysis: A Look at Growth Amidst Financial Challenges

Sonida Senior Living, Inc. (NASDAQ: SNDA), a key player in the healthcare sector, operates senior housing communities across the United States. With a market capitalization of approximately $496 million, Sonida..

Immunome, Inc. (IMNM) Stock Analysis: A Biotech Firm with a 45% Upside Potential

Investors interested in the biotechnology sector should pay close attention to Immunome, Inc. (NASDAQ: IMNM), a clinical-stage company focused on innovative cancer therapies. With a current market capitalization of $1.44..

AngioDynamics, Inc. (ANGO) Stock Analysis: A 57.85% Potential Upside Sparks Investor Interest

AngioDynamics, Inc. (NASDAQ: ANGO) is making waves in the healthcare sector with its innovative medical technology solutions. Despite a challenging financial landscape, the company presents a compelling opportunity for investors,..

Replimune Group, Inc. (REPL) Stock Analysis: Navigating Biotech’s Volatile Waters with a Precise Focus on Cancer Immunotherapy

Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, is making strides in the healthcare sector with its innovative approach to oncolytic immunotherapies aimed at treating cancer. Despite its promising..

EyePoint Pharmaceuticals, Inc. (EYPT) Stock Analysis: Exploring the 197.98% Upside Potential

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) is capturing the attention of investors with its compelling growth potential and innovative approach in the biotechnology sector. Headquartered in Watertown, Massachusetts, EyePoint specializes in..

Akso Health Group (AHG) Stock Analysis: Navigating a 415.8% Revenue Growth in China’s Medical Distribution Sector

Akso Health Group (NASDAQ: AHG) is making waves in the healthcare sector, particularly within the medical distribution industry in China. With a market capitalization of $911.67 million, Akso Health Group..

Oruka Therapeutics, Inc. (ORKA) Stock Analysis: A Promising 62.73% Upside in the Biotech Arena

Oruka Therapeutics, Inc. (ORKA), a clinical-stage biopharmaceutical company based in Menlo Park, California, is making waves in the biotechnology sector by focusing on innovative monoclonal antibody therapeutics. With a market..

Humacyte, Inc. (HUMA): Analyst Ratings Highlight a 387% Potential Upside for Innovative Biotech Pioneer

Humacyte, Inc. (NASDAQ: HUMA) stands out in the biotechnology sector with its cutting-edge approach to developing off-the-shelf, implantable bioengineered human tissues. As the healthcare landscape continues to evolve, Humacyte’s pioneering..

Ginkgo Bioworks Holdings, Inc. (DNA) Stock Analysis: Navigating a Challenging Landscape with -11.70% Revenue Growth

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), a prominent player in the biotechnology sector, presents a unique case study for investors considering the intersection of innovation and financial performance. With a..

Opthea Limited (OPT) Stock Analysis: Navigating the -70.67% Downside Amid Biotech Ambitions

Opthea Limited (NASDAQ: OPT), an Australian biotechnology firm, is at the forefront of developing cutting-edge therapies for ocular conditions. With its core research concentrated on vascular endothelial growth factors (VEGF)..

Standard BioTools Inc. (LAB) Stock Analysis: Is a 37.6% Upside Within Reach for This Healthcare Innovator?

Standard BioTools Inc. (NASDAQ: LAB), a dynamic player in the medical devices industry, has piqued investor interest with a potential upside of 37.6%, according to recent analyst ratings. Based in..

Autolus Therapeutics plc (AUTL) Stock Analysis: Exploring a 472.75% Potential Upside in T Cell Therapy Innovation

Autolus Therapeutics plc (NASDAQ: AUTL), a pioneering player in the biotechnology sector, is capturing investor attention with its innovative T cell therapies aimed at treating cancer and autoimmune diseases. Headquartered..

Akebia Therapeutics, Inc. (AKBA) Investor Outlook: Exploring a Potential Upside of 153.42%

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a biopharmaceutical company nestled in the healthcare sector, is gaining traction among investors intrigued by its promising potential upside. With a market capitalization of $774.22..

Zevra Therapeutics, Inc. (ZVRA)

⚠️ No article content returned.

..
Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds